|Spectral Diagnostics Inc.|
135-2 The West Mall
ON M9C 1C2
Canada - Map
Spectral Diagnostics Inc. develops and commercializes theranostic treatment for severe sepsis in North America. The companys products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. It is also involved in the development, production, and marketing of recombinant cardiac proteins, antibodies, and calibrators for use in research and development, as well as in products manufactured by other diagnostic companies. The company was founded in 1991 and is headquartered in Toronto, Canada.
|Dr. Paul M. Walker M.D., Ph.D., F.R.C.S.,
Chief Exec. Officer, Pres, Director and Member of Disclosure Committee
|Mr. Anthony Businskas CA,
Chief Financial Officer, Exec. VP, Sec. and Member of Disclosure Committee
|Dr. Gualtiero Guadagni ,
VP of Sales and Marketing
|Ms. Debra-Anne M. Foster RN, B.Sc., CCRC,
VP of Clinical Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in CAD.|